Payment overview · 2025
General Payments
$57,000.44
154 reported records · 27 companies
Healthcare provider profile · identity verified
Nilay Ramesh Shah, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Clinical Neurophysiology · FAIR LAWN, NJ · NPI 1154372621
Verified facts
What the public records show
CMS Open Payments records show Nilay Ramesh Shah, MD received $57,000.44 in general payments during 2025 across 154 reported records.
TG Therapeutics, Inc. accounted for 80.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gammaked, Gamunex-C, Hizentra, Valtoco, Xcopri, Zeposia.
CSL Behring reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Hizentra as an associated drug or biological on 13634 records involving 4691 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Hizentra by this doctor in 2024.
CSL Behring reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Privigen as an associated drug or biological on 464 records involving 289 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Privigen by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZEPOSIA as an associated drug or biological on 9581 records involving 2490 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Zeposia by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZEPOSIA as an associated drug or biological on 976 records involving 466 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Zeposia by this doctor in 2024.
Grifols USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gamunex-C as an associated drug or biological on 3977 records involving 2134 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Gamunex-C by this doctor in 2024.
Kedrion Biopharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAKED as an associated drug or biological on 761 records involving 541 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Gammaked by this doctor in 2024.
Neurelis, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VALTOCO as an associated drug or biological on 16082 records involving 5567 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Valtoco by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Nurtec Odt by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Xcopri by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $45,653.70 | 80.1% | 32 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $5,605.34 | 9.8% | 6 | 2025 |
| Kedrion Biopharma, Inc. | Unresolved — no canonical attribution shown | $2,000.00 | 3.5% | 1 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$1,410.03 | 2.5% | 6 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $431.85 | 0.8% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $222.30 | 0.4% | 4 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $222.13 | 0.4% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $174.35 | 0.3% | 11 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $164.54 | 0.3% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $143.97 | 0.2% | 11 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $140.96 | 0.2% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $136.63 | 0.2% | 26 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $135.61 | 0.2% | 7 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $71.29 | 0.1% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $70.39 | 0.1% | 4 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $66.08 | 0.1% | 4 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$64.38 | 0.1% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $53.97 | 0.1% | 3 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $53.20 | 0.1% | 3 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.12 | 0.1% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $31.72 | 0.1% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $30.32 | 0.1% | 2 | 2025 |
| BIOTRONIK NRO, Inc. | Unresolved — no canonical attribution shown | $20.93 | 0.0% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $17.10 | 0.0% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $16.81 | 0.0% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $15.02 | 0.0% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.70 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $45,415.70 | 16 |
| Travel and Lodging | $4,896.00 | 14 |
| Food and Beverage | $3,279.62 | 119 |
| Consulting Fee | $2,000.00 | 1 |
| Honoraria | $1,375.00 | 3 |
| Education | $34.12 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $45,653.70 | 32 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation, E.R. Squibb & Sons, L.L.C. | $5,620.36 | 7 | 2025 |
Source payment records
|
|||||
| Albuked Normalized: albuked |
Biological | Kedrion Biopharma, Inc. | $2,000.00 | 1 | 2025 |
Source payment records
|
|||||
| GAMMAKED Normalized: gammaked |
Biological | Kedrion Biopharma, Inc. | $2,000.00 | 1 | 2025 |
Source payment records
|
|||||
| KEDRAB Normalized: kedrab |
Biological | Kedrion Biopharma, Inc. | $2,000.00 | 1 | 2025 |
Source payment records
|
|||||
| KOATE Normalized: koate |
Biological | Kedrion Biopharma, Inc. | $2,000.00 | 1 | 2025 |
Source payment records
|
|||||
| RhoGAM Ultra-Filtered PLUS Normalized: rhogam ultra filtered plus |
Biological | Kedrion Biopharma, Inc. | $2,000.00 | 1 | 2025 |
Source payment records
|
|||||
| XCOPRI Normalized: xcopri |
Drug | SK Life Science, Inc. | $1,375.00 | 3 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $431.85 | 11 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $222.30 | 4 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $174.35 | 11 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $164.54 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $143.97 | 11 | 2025 |
Source payment records
|
|||||
| ZIIHERA Normalized: ziihera |
Drug | JAZZ PHARMACEUTICALS INC. | $140.96 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $136.63 | 26 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $135.61 | 7 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $135.61 | 7 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $97.13 | 1 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $71.29 | 4 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $70.39 | 4 | 2025 |
Source payment records
|
|||||
| Apokyn Normalized: apokyn |
Drug | MDD US Operations, LLC | $66.08 | 4 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $64.38 | 4 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $53.97 | 3 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $53.20 | 3 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $34.12 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $31.72 | 2 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $30.32 | 2 | 2025 |
Source payment records
|
|||||
| Prospera Normalized: prospera |
Device | BIOTRONIK NRO, Inc. | $20.93 | 1 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $16.81 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $13.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GAMMAKED gammaked |
2025 | Gammaked | 2024 | 120 | exact normalized | Medicare Part D |
| Gamunex-C gamunex c |
2025 | Gamunex-C | 2024 | 54 | exact normalized | Medicare Part D |
| Hizentra hizentra |
2025 | Hizentra | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VALTOCO valtoco |
2025 | Valtoco | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XCOPRI xcopri |
2025 | Xcopri | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZEPOSIA zeposia |
2025 | Zeposia | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| CSL Behring Exact reporting entity; no affiliate inference |
2025 | Hizentra open payments reported associated product |
CMS Open Payments — General Payments 13634 supporting records · 4691 recipient NPIs · example record 1232339012 |
Hizentra · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| CSL Behring Exact reporting entity; no affiliate inference |
2025 | Privigen open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 289 recipient NPIs · example record 1232339064 |
Privigen · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ZEPOSIA open payments reported associated product |
CMS Open Payments — General Payments 9581 supporting records · 2490 recipient NPIs · example record 1184377823 |
Zeposia · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ZEPOSIA open payments reported associated product |
CMS Open Payments — General Payments 976 supporting records · 466 recipient NPIs · example record 1184381876 |
Zeposia · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Grifols USA, LLC Exact reporting entity; no affiliate inference |
2025 | Gamunex-C open payments reported associated product |
CMS Open Payments — General Payments 3977 supporting records · 2134 recipient NPIs · example record 1249529381 |
Gamunex-C · 2024 Exact normalized brand match · 1 Part D row |
54 | 12 |
| Kedrion Biopharma, Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAKED open payments reported associated product |
CMS Open Payments — General Payments 761 supporting records · 541 recipient NPIs · example record 1206766586 |
Gammaked · 2024 Exact normalized brand match · 1 Part D row |
120 | 14 |
| Neurelis, Inc. Exact reporting entity; no affiliate inference |
2025 | VALTOCO open payments reported associated product |
CMS Open Payments — General Payments 16082 supporting records · 5567 recipient NPIs · example record 1219183925 |
Valtoco · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Octagam | Immun Globg(Igg)/Malt/Iga Ov50 | 463 | 46 |
| Memantine Hcl | Memantine Hcl | 359 | 107 |
| Gammaplex | Immun Glob G(Igg)/Gly/Iga 0-50 | 355 | 37 |
| Donepezil Hcl | Donepezil Hcl | 232 | 73 |
| Gabapentin | Gabapentin | 230 | 83 |
| Lamotrigine | Lamotrigine | 203 | 56 |
| Sodium Chloride | 0.9 % Sodium Chloride | 148 | 62 |
| Gammaked | Immune Globul G/Gly/Iga Avg 46 | 120 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 109 | 33 |
| Levetiracetam | Levetiracetam | 106 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 91 | 30 |
| Amantadine | Amantadine Hcl | 76 | 27 |
| Amitriptyline Hcl | Amitriptyline Hcl | 66 | 24 |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 56 | suppressed |
| Xcopri | Cenobamate | 55 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 25 |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 54 | 12 |
| Baclofen | Baclofen | 51 | 13 |
| Nurtec Odt | Rimegepant Sulfate | 42 | suppressed |
| Topiramate | Topiramate | 34 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 32 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 31 | 29 |
| Diazepam | Diazepam | 26 | 12 |
| Lacosamide | Lacosamide | 21 | suppressed |
| Zonisamide | Zonisamide | 21 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Zeposia | Ozanimod Hydrochloride | 19 | suppressed |
| Valtoco | Diazepam | 18 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Adrenalin | Epinephrine | 15 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Carbamazepine Er | Carbamazepine | 14 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 14 | suppressed |
| Kesimpta Pen | Ofatumumab | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Hizentra | Immun Glob G(Igg)/Pro/Iga 0-50 | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $57,000.44 · 154 records | TG Therapeutics, Inc. | ACTHAR, AUSTEDO XR, Albuked, Apokyn, BRIUMVI, GAMMAKED, Gamunex-C, HYQVIA, Hizentra, INGREZZA, KEDRAB, KESIMPTA, KEVEYIS, KOATE, Ocrevus Zunovo, PANZYGA, PONVORY, PURIFIED CORTROPHIN GEL, Prospera, RhoGAM Ultra-Filtered PLUS, Symbravo, TYSABRI, ULTOMIRIS, UPLIZNA, VALTOCO, VUMERITY, VYEPTI, VYVGART, XCOPRI, ZEPOSIA, ZIIHERA | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gammaked play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with CSL Behring?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error